drugset
drugset / Trial / NCT07213310

Drug-Drug Interaction Study to Evaluate the Effect of DWC202511 or DWC202512 With DWP16001 in Healthy Adults

NCT07213310 ↗

Phase 1 Completed 18 enrolled Daewoong Pharmaceutical Co. LTD.
NaSingle-groupOpen-labelTreatment

Summary

Drug-Drug Interaction Study to Evaluate the Effect of DWC202511 or DWC202512 With DWP16001 in Healthy Adults

Timeline

Start
2025-11-09
Primary completion
2026-01-07
Completion
2026-01-07

Drugs

EvaluationDrugModalityDoseRoute
Subject DWC202511 Unknown 500 mg Oral
Subject DWC202512 Unknown — Oral
Subject Enavogliflozin Small molecule — Oral

Indications

No indication recorded.